tbuckley/cabot-search huggingface dataset:
Efficacy of short-duration (twice weekly) intralesional sodium stibogluconate in treatment of cutaneous leishmaniasis in India
Authors: R.A. Bumb, R.D. Mehta, B.C. Ghiya, R. Jakhar, N. Prasad, P. Soni, C. Lezama-Davila, A.R. Satoskar
Journal: British Journal of Dermatology (2010)

Background Cutaneous leishmaniasis (CL) is caused by Leishmania major and L. tropica in the old world. Bikaner, the ‘Thar Desert’, situated in the north‐western corner of India, is an endemic pocket for CL caused by L. tropica. Skin lesions of CL heal slowly, causing disfiguring scars if remaining untreated. Current recommended treatment for CL comprises systemic administration of sodium stibogluconate (SSG) for 2–3 weeks. Five to seven injections of SSG intralesionally have also been found to be effective. Objectives To determine the efficacy of a short‐duration, twice‐weekly intralesional SSG treatment for CL. Methods Two hundred and twenty patients with CL having 298 lesions were included in the present study. They were divided into groups A and B (110 patients each). Patients were treated with five to seven intralesional injections of SSG in doses of 50 mg cm−2 of lesion either once (group A) or twice (group B) weekly. Improvement was recorded at 6, 8, 10, 12, 16, 20 and 24 weeks and the rate of complete cure was compared. Results Complete cure rate at 6, 8 and 10 weeks was higher (20%, 57% and 73%, respectively) in group B as compared with group A (12%, 36% and 62%, respectively). The differences in cure rates at these time points were statistically significant (P < 0·05). The complete cure rate at 24 weeks was similar in both groups (96% in group B and 92% in group A). The remaining 4% and 8% of patients in groups B and A were ‘nonresponders’, respectively. No major side‐effects were observed in either group. In all cured cases, there were no relapses reported up to 2 years after treatment. Conclusions A short‐duration, twice‐weekly intralesional SSG treatment for CL accelerates cure and is highly effective and well tolerated.
A doctor who changed my practice: Putting women in control
Authors: S. Bewley
Journal: BMJ (2000)

As a research registrar in obstetrics and gynaecology I was moonlighting and gaining extra experience doing family planning and youth clinics. Unlike most of my previous training I was expected to sit in and then be observed by a senior doctor. It was my great fortune to work with Fay Hutchinson, the medical director of the Brook Advisory Service, because she completely changed my approach to patients.

Many of the women coming for contraception, pregnancy testing, and abortion advice were young and had never had vaginal examinations or smears. They would be …
Serum IgA reactivity against GroEL of<i>Streptococcus sanguinis</i>and human heterogeneous nuclear ribonucleoprotein A2/B1 in patients with Behçet disease
Authors: S.B. Cho, Z. Zheng, K.J. Ahn, M.J. Choi, S. Cho, D.-Y. Kim, H.S. Lee, D. Bang
Journal: British Journal of Dermatology (2012)

Infectious agents, especially Streptococcus sanguinis and herpes simplex virus, have long been postulated as major triggering factors for Behçet disease (BD).To identify an anti-S. sanguinis antigen reacting with serum IgA antibody in patients with BD.We detected a target protein by proteomics analysis and evaluated serum IgA reactivity of 100 patients with BD against the identified streptococcal target protein and human heterogeneous nuclear ribonucleoprotein (hnRNP) A2/B1. Homologous epitope sequences between the streptococcal target protein and human hnRNP A2/B1 were also evaluated.Four protein bands were detected by immunoprecipitation, and chaperonin GroEL was identified by a proteomics analysis. Reactivity of serum IgA against recombinant S. sanguinis GroEL was detected in 77 of 100 patients with BD (77%) and in 21 of 70 healthy controls (30%). In addition, reactivity of serum IgA against human recombinant hnRNP A2/B1 was seen in 79 of 100 patients with BD (79%) and in eight of 70 healthy controls (11%). Among the eight distinctive epitopes with significant homology between S. sanguinis GroEL and human hnRNP A2/B1, the serum IgA reactivity of patients with BD was markedly higher with epitope 3 (hnRNP A2/B1 peptide 33-46 and GroEL peptide 57-70) and epitope 6 (hnRNP A2/B1 peptide 177-188 and GroEL peptide 347-358).We identified an S. sanguinis GroEL protein as a target of serum anti-S. sanguinis IgA antibody reactivity in patients with BD. In addition, patients with BD exhibited serum IgA reactivity against homologous epitope regions between S. sanguinis GroEL and human hnRNP A2/B1.
Abstract 702: DCVex(TM): A novel integration-deficient lentivector technology that incorporates genetic and post-translational elements to target dendritic cells
Authors: Semih U. Tareen, Brenna Kelley-Clarke, Christopher J. Nicolai, Megan M. Slough, Chintan D. Vin, Neal Van Hoeven, Scott H. Robbins, Jan H. ter Meulen, Peter Berglund
Journal: Cancer Research (2014)

Abstract With the goal of creating antigen-directed immunotherapeutics that can be safely administered directly to patients, Immune Design has developed a platform of novel integration-deficient lentiviral vectors that target and deliver antigen-encoding nucleic acids to dendritic cells (DCs) in order to promote the activation of antigen-specific effector CD8 T cells. This platform, termed DCVex(TM), utilizes a novel genetic variant of a Sindbis virus envelope glycoprotein with post-translational carbohydrate modifications in combination with Vpx, a SIVmac viral accessory protein, to achieve efficient targeting and transduction of DCs. In addition, DCVex(TM) incorporates safety features in its design that include redundant mechanisms to render DCVex(TM) integration-deficient, as well as genetic modifications that eliminate psi-gag recombination between split genome components. The characteristics that allow DCVex(TM) to specifically transduce human DCs and the advances that DCVex(TM) brings to conventional third-generation lentiviral vector design demonstrate its potential as a vaccine designed to utilize DCs for cancer immunotherapy. Citation Format: Semih U. Tareen, Brenna Kelley-Clarke, Christopher J. Nicolai, Megan M. Slough, Chintan D. Vin, Neal Van Hoeven, Scott H. Robbins, Jan H. ter Meulen, Peter Berglund. DCVex(TM): A novel integration-deficient lentivector technology that incorporates genetic and post-translational elements to target dendritic cells. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 702. doi:10.1158/1538-7445.AM2014-702
Role of Protein Phosphatase Magnesium‐Dependent 1A and Anti–Protein Phosphatase Magnesium‐Dependent 1A Autoantibodies in Ankylosing Spondylitis
Authors: Yong‐Gil Kim, Dong Hyun Sohn, Xiaoyan Zhao, Jeremy Sokolove, Tamsin M. Lindstrom, Bin Yoo, Chang‐Keun Lee, John D. Reveille, Joel D. Taurog, William H. Robinson
Journal: Arthritis & Rheumatology (2014)

Although ankylosing spondylitis (AS) is driven by immune-mediated processes, little is known about the presence and role of autoantibodies in this disease. This study was undertaken to investigate whether autoantibodies occur in and are involved in AS.We performed human protein microarray analysis of sera derived from patients with AS or other autoimmune disorders to identify autoantibodies associated specifically with AS, and identified autoantibody targeting of protein phosphatase magnesium-dependent 1A (PPM1A) in AS. We performed enzyme-linked immunosorbent assay (ELISA) analysis of sera from 2 independent AS cohorts to confirm autoantibody targeting of PPM1A, and to assess associations between levels of anti-PPM1A antibodies and AS disease severity or response to anti-tumor necrosis factor (anti-TNF) therapy (as measured by Bath AS Disease Activity Index [BASDAI] score). Levels of anti-PPM1A antibodies were also evaluated in sera from rats transgenic for HLA-B27 and human β2 -microglobulin. The expression of PPM1A was assessed by immunohistochemistry in synovial tissue samples from patients with AS, rheumatoid arthritis, or osteoarthritis. The role of PPM1A in osteoblast differentiation was investigated by gene knockdown and overexpression.AS was associated with autoantibody targeting of PPM1A, and levels of anti-PPM1A autoantibodies were significantly higher in patients with more advanced sacroiliitis and correlated positively with BASDAI score after treatment with anti-TNF agents. The levels of anti-PPM1A autoantibodies were also higher in the sera of transgenic rats that are prone to develop spondyloarthritis than in those that are not. PPM1A was expressed in AS synovial tissue, and PPM1A overexpression promoted osteoblast differentiation, whereas PPM1A knockdown suppressed it.Anti-PPM1A autoantibodies are present in AS, and our findings suggest that PPM1A may contribute to the pathogenic bone ankylosis characteristic of AS.
Abstract 17168: Factors Influencing Detection of Gadolinium Delayed Enhancement in Acute Myopericarditis
Authors: Maria Luaces, Juan Pablo Florez, Mar Erdociain, Joaquin Perez, Ana Bustos, Alberto de Agustin, Leopoldo Pérez de Isla, Carlos Macaya
Journal: Circulation (2014)

Objective: to correlate the presence of delayed enhancement (DE) in acute myopericarditis with clinical and echocardiographic and other cardiac MRI (CMR) findings.

Methods: Retrospective analysis of all patients admitted for acute myoperdicarditis and studied with CMR from 2007-2014. Epidemiological and laboratory data were registered, as well as cardiac imaging information from CMR and echocardiography. The optimum sensitivity and specificity of threshold values of Troponin- I (TnI) to predict DE were examined by ROC analysis. A logistic regression analysis predicted the presence of DE for different values of TnI.

Results: 49 episodes were included. Mean age was 31.8 (12.5) years and 75.5% were male. TnI was augmented in all cases and its mean value was 15.4 ng/mL (IQR 23-41). Mean length of in-hospital stay was 5.3 (3) days. Mean time until CMR was performed was 6.2 (6.6) days (the table). DE was detected in 63.3% of cases. According to the ROC analysis, a threshold value of TnI ≥ 7.48 ng/mL had a sensitivity of 84% and specificity of 66% to predict presence of DE (the figure). A regression analysis included age, LV mass, left atrial size and TnI but only TnI was an statistically significant factor to predict DE [OR = 1.14, CI 95%= (1.04-1.26), p= 0.006].

Conclusions: In patients admitted for acute myopericarditis with elevated TnI undergoing cardiac MRI, gadolinium delayed enhancement is present in 63.3% of cases. Most patients have preserved LVEF with no pericardial effusion. A threshold value of TnI ≥ 7.48 ng/mL predicts detection of delayed enhancement with a 85% likelihood.

   ![][1]    ![][2]  [1]: /embed/graphic-1.gif
 [2]: /embed/graphic-2.gif
Abstract 3735: Monitoring the level of the universal nucleotide AMP in diverse enzymatic reactions using bioluminescent homogenous assay platform
Authors: Said A. Goueli, Kevin Hsiao, Hicham Zegzouti, Subhanjan Mondal
Journal: Cancer Research (2014)

Abstract Adenine nucleotides are major determinants of the energy status of the cell and thus any modulation of their cellular concentration has significant consequences to cellular metabolism, cellular growth and cell death. Many biochemical reactions that generate AMP as a reaction product are pivotal players in a variety of signaling pathways and thus are considered validated drug targets. These include enzymes involved in protein ubiquitination (Ubiquitin ligases), protein synthesis (aminoacyl tRNA synthetases), second messenger signaling (cAMP-phosphodiesterases), and DNA synthesis and repair (prokaryotic and eukaryotic DNA ligases). Therefore, an assay that monitors the activity of these enzymes is desirable in the search for selective modulators and the development of novel therapeutics. As AMP is a common product of these enzymatic reactions, the development of an assay that monitors AMP in a homogenous and sensitive fashion will have significant impact in these diverse areas of research. In addition, enzyme reactions that generate products which can be converted to AMP can be also monitored using this assay. We demonstrate the utility of this assay platform in monitoring the activity of cAMP-PDE, aminoacyl tRNA synthetases, ubiquitin ligases, DNA ligases. Furthermore, enzyme reactions such as methyltransferases that produce product (SAH) which can be converted to AMP can be monitored using this assay platform Citation Format: Said A. Goueli, Kevin Hsiao, Hicham Zegzouti, Subhanjan Mondal. Monitoring the level of the universal nucleotide AMP in diverse enzymatic reactions using bioluminescent homogenous assay platform. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3735. doi:10.1158/1538-7445.AM2014-3735
Scientific Foundations of Obstetrics and Gynaecology.
Authors: Elliot Elias Philipp, Josephine Barnes, Michael Newton
Journal: Annals of Internal Medicine (1970)

Part 1 General: advances in cell biology, Gerard I.Evan principles of human cytogenetics, Joe Leigh Simpson and Avirchan T.Tharapel genetic counselling, Frances A.Flinter and A.Caroline Berry immunology of human pregnancy, Y.W.Loke and Ashley King human semen, Anne M.Jequier. Part 2 Female genital structure and function: the bones, joints and ligaments of the female, J.Joseph the vulva, vagina and urethra, and the musculature of the pelvic floor, C.P.Wendell Smith and Paula M.Wilson lymphatics of the pelvis, C.N.Hudson neurology and neurophysiology of the female genital organs, Michael Swash functional anatomy of the cervix and uterus, Max Elstein and Eric Chantler the fallopian tube, Ivo A.Brosins the ovary - development and structure, T.G.Baker and Wai Sum O. urinary continence and urodynamic investigation of female incontinence, Linda Cardozo and Stuart L.Stanton physiology of human female sexual response, Alan J.Riley and Eric J.Trimmer.
Dose optimization for near-infrared fluorescence sentinel lymph node mapping in patients with melanoma
Authors: J.R. van der Vorst, B.E. Schaafsma, F.P.R. Verbeek, R.J. Swijnenburg, M. Hutteman, G.J. Liefers, C.J.H. van de Velde, J.V. Frangioni, A.L. Vahrmeijer
Journal: British Journal of Dermatology (2012)

Regional lymph node involvement is the most important prognostic factor in cutaneous melanoma. As only 20% of patients with melanoma have occult nodal disease and would benefit from a regional lymphadenectomy, the sentinel lymph node (SLN) biopsy was introduced. Near-infrared (NIR) fluorescence has been hypothesized to improve SLN mapping. To assess the potential of intraoperative NIR fluorescence imaging to improve SLN mapping in patients with melanoma and to examine the optimal dose of indocyanine green adsorbed to human serum albumin (ICG:HSA). Fifteen consecutive patients with cutaneous melanoma underwent the standard SLN procedure using (99m) technetium-nancolloid and patent blue. In addition, intraoperative NIR fluorescence imaging was performed after injection of 1·6 mL of 600, 800, 1000 or 1200 μmolL(-1) of ICG: HSA in four quadrants around the primary excision scar. NIR fluorescence SLN mapping was successful in 93% of patients. In one patient, no SLN could be identified using either conventional methods or NIR fluorescence. A total of 30 SLNs (average 2·0, range 1-7) were detected, 30 radioactive (100%), 27 blue (73%) and 30 NIR fluorescent (100%). With regard to the effect of concentration on signal-to-background ratios a trend (P=0·066) was found favouring the 600, 800 and 1000 μmol L(-1) groups over the 1200 μmol L(-1) group. This study demonstrates feasibility and accuracy of SLN mapping using ICG: HSA. Considering safety, cost and pharmacological characteristics, an ICG: HSA concentration of 600 μmolL(-1) appears optimal for SLN mapping in cutaneous melanoma, although lower doses need to be assessed.
Abstract 4609: Incomplete Neointimal Coverage Persists Beyond 4 Years After Sirolimus-Eluting Stent Implantation: Angioscopic Follow-up Study in Patients
Authors: Masaki Awata, Shinsuke Nanto, Masaaki Uematsu, Takakazu Morozumi, Tetsuya Watanabe, Masashi Fujita, Toshinari Onishi, Osamu Iida, Fusako Sera, Shin Okamoto, Haruyo Yasui, Kuniyasu Ikeoka, Nobuaki Tanaka, Takayuki Ishihara, Tomoharu Dohi, Tuyoshi Mishima, Seiki Nagata
Journal: Circulation (2009)

Background- Several large cohort studies up to 4 years revealed low but persistent risk of very late stent thrombosis following drug-eluting stent implantation. This may be attributed to incomplete...
Effects of Intermittent Transdermal Nitroglycerin on Occurrence of Ischemia After Patch Removal: Results of the Second Transdermal Intermittent Dosing Evaluation Study (TIDES-II) fn1fn1This study was supported by a grant from Ciba-Geigy Pharmaceuticals, Summit, New Jersey.
Authors: Carl J. Pepine, Larry M. Lopez, Dawn M. Bell, Eileen M. Handberg-Thurmond, Ronald G. Marks, Susan McGorray
Journal: Journal of the American College of Cardiology (1997)
Abstract 4254: ESE1 binds to beta catenin and modulates its expression
Authors: Xu-yu Yang, Kui Jin Kim, Hong Jun Shao, Seong-Ho Lee
Journal: Cancer Research (2014)

Abstract ESE-1 is an epithelium-specific transcription factor that functions in the differentiation of intestinal epithelial cells. ESE-1's structure predicts its interaction with a number of other proteins with various cellular functions. Previously we have shown that tolfenamic acid (TA) could induce nuclear translocation of ESE1 in colorectal cancer cells, and plays a critical role in the activation of apoptosis. Here we show that β-catenin, an important protein regulating cell-cell adhesion and gene transcription, binds and colocalizes with ESE-1 in cell cytoplasm. The binding sites were mapped to carboxy terminus ESE-1, which includes the ETS domain, and N-terminus of β-catenin, which contains several important phosphorylation sites. C-terminus of ESE1 also binds to α-catenin, and ESE1/ β-catenin interaction was abrogated with suppression of either β-catenin or α-catenin in HEK293 cells by si RNA treatment; moreover, suppression of both α-catenin and β-catenin further impaired ESE1/ β-catenin binding. Furthermore, knockdown of endogenous ESE1 significantly decreased β-catenin level in HCT116 cells. Current data support a role of ESE1 in the regulation of β-catenin function in colon cancer. Citation Format: Xu-yu Yang, Kui Jin Kim, Hong Jun Shao, Seong-Ho Lee. ESE1 binds to beta catenin and modulates its expression. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4254. doi:10.1158/1538-7445.AM2014-4254
Abstract 17101: Low-intensity Anticoagulant Treatment in Chinese Patients with Mechanical Heart Valve Prostheses: Early Outcomes of a Prospective, Multicenter Registry in China
Authors: JIA HU, BO FU, Jian-ping Xu, Ying-kang Shi, Li Dong
Journal: Circulation (2014)

Background: Current guidelines recommend vitamin K antagonist treatment with relatively higher international normalized ratio (INR) targets for patients with mechanical heart valve prostheses. However, there is lack of data from large clinical trials about the outcomes of low-intensity anticoagulant treatment in Chinese patients with mechanical heart valves. Methods: The Low-intensity Anticoagulation Therapy after Heart Valve Replacement is an ongoing multicenter, prospective, observational cohort study (ChiCTR-OCH-10001185). Between January 2011 and August 2013, qualified patients from 34 cardiac centers in China mainland were recruited in the Anticoagulation Therapy Database of Chinese Patients after Heart Valve Replacement. Baseline characteristics were collected and patients were followed up for anticoagulant treatment, INRs and adverse events till March 2014. Results: The database recruited 11,769 patients, and 11,040 patients (93.8%) undergoing mechanical heart valve replacement were analyzed in this study. The mean age was 48.9±11.5 years and 6,227 patients (56.4%) were female. A total of 9,870 patients (89.4%) of the baseline population completed at least 6 months follow-up. The median follow-up time was 1.2 years (range 0.5-2.2). For all 9,870 patients, 143,115 measurements of the INR were obtained. The average warfarin dosage was 2.98±1.16mg/d and the mean INR was 1.81±0.46, and 88.7% patients had an INR level≤2.5 during the follow-up period. The incidence of hemorrhagic events was the lowest in patients with an INR≤2.0, whereas the risk of thromboembolic complications in this group of patients was not significantly increased (Table 1). Conclusions: Low-intensity anticoagulation with an INR of 1.5 to 2.5 is safe and effective for Chinese patients with mechanical heart valves in short-term. The optimal INR targets for mechanical valve recipients with different implanting positions and risk factors require further investigation.
Tre Puttini Feriti
Authors: M. Therese Southgate
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Are atypical depression, borderline personality disorder and bipolar II disorder overlapping manifestations of a common cyclothymic diathesis?
Authors: GIULIO PERUGI, MICHELE FORNARO, HAGOP S. AKISKAL
Journal: World Psychiatry (2011)

The constructs of atypical depression, bipolar II disorder and borderline personality disorder (BPD) overlap. We explored the relationships between these constructs and their temperamental underpinnings. We examined 107 consecutive patients who met DSM-IV criteria for major depressive episode with atypical features. Those who also met the DSM-IV criteria for BPD (BPD+), compared with those who did not (BPD-), had a significantly higher lifetime comorbidity for body dysmorphic disorder, bulimia nervosa, narcissistic, dependent and avoidant personality disorders, and cyclothymia. BPD+ also scored higher on the Atypical Depression Diagnostic Scale items of mood reactivity, interpersonal sensitivity, functional impairment, avoidance of relationships, other rejection avoidance, and on the Hopkins Symptoms Check List obsessive-compulsive, interpersonal sensitivity, anxiety, anger-hostility, paranoid ideation and psychoticism factors. Logistic regression revealed that cyclothymic temperament accounted for much of the relationship between atypical depression and BPD, predicting 6 of 9 of the defining DSM-IV attributes of the latter. Trait mood lability (among BPD patients) and interpersonal sensitivity (among atypical depressive patients) appear to be related as part of an underlying cyclothymic temperamental matrix.